ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.66 USD
-0.72 (-1.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.68 +0.02 (0.03%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Company Summary
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.
Company Summary
General Information
ANI Pharmaceuticals, Inc
210 Main Street West
Baudette, MN 56623
Phone: 218-634-3500
Fax: 218-634-3540
Web: http://www.anipharmaceuticals.com
Email: ir@anipharmaceuticals.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.07 |
Current Year EPS Consensus Estimate | 4.82 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 60.38 |
52 Week High | 70.50 |
52 Week Low | 48.20 |
Beta | 0.71 |
20 Day Moving Average | 479,609.84 |
Target Price Consensus | 81.20 |
4 Week | -3.28 |
12 Week | -6.31 |
YTD | 8.20 |
4 Week | -4.43 |
12 Week | -10.29 |
YTD | -9.50 |
Shares Outstanding (millions) | 21.04 |
Market Capitalization (millions) | 1,255.30 |
Short Ratio | NA |
Last Split Date | 7/18/2013 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 12.39 |
Trailing 12 Months | 13.26 |
PEG Ratio | NA |
vs. Previous Year | -32.08% |
vs. Previous Quarter | -24.21% |
vs. Previous Year | 18.44% |
vs. Previous Quarter | 0.44% |
Price/Book | 2.75 |
Price/Cash Flow | 9.30 |
Price / Sales | 2.33 |
6/30/24 | 15.64 |
3/31/24 | 17.15 |
12/31/23 | 18.06 |
6/30/24 | 7.63 |
3/31/24 | 8.29 |
12/31/23 | 8.38 |
6/30/24 | 3.97 |
3/31/24 | 3.95 |
12/31/23 | 3.57 |
6/30/24 | 3.07 |
3/31/24 | 3.12 |
12/31/23 | 2.81 |
6/30/24 | 12.85 |
3/31/24 | 14.28 |
12/31/23 | 14.72 |
6/30/24 | 5.01 |
3/31/24 | 6.87 |
12/31/23 | 3.86 |
6/30/24 | 6.59 |
3/31/24 | 8.32 |
12/31/23 | 4.08 |
6/30/24 | 21.66 |
3/31/24 | 21.53 |
12/31/23 | 21.13 |
6/30/24 | 1.82 |
3/31/24 | 1.77 |
12/31/23 | 1.71 |
6/30/24 | 0.62 |
3/31/24 | 0.63 |
12/31/23 | 0.66 |
6/30/24 | 37.17 |
3/31/24 | 37.38 |
12/31/23 | 38.36 |